Shares of Silo Pharma, Inc. (SILO) are surging more than 50% Friday morning after the company reported positive data for its drug candidate SPU-21 for the treatment of Arthritis.
The company today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents.
Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).
SILO, currently at $5.21, has traded in the range of $0.17-$12.45 in the last 1 year.
Source: Read Full Article
Bitcoin [BTC]: SegWit transactions’ volume peaking on the Bitcoin network
Bitcoin [BTC] hashrate witnesses a sharp incline: Miners can breakeven at $7300
Bitcoin Rejected at $7,500; A Much Larger Drop Could Be Imminent
CBS News President David Rhodes To Step Down
Strike's Jack Maller Announces Shopify Integration, Partners With Blackhawk And NCR To Facilitate Lightning Network Payments